Cargando…
Triple-negative breast cancer: treatment challenges and solutions
Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and progesterone receptors and the absence of HER2 overexpression. These cancers represent a heterogeneous breast cancer subtype with a poor prognosis. Few systemic treatment options exist besides the use of chemotherapy (...
Autores principales: | Collignon, Joëlle, Lousberg, Laurence, Schroeder, Hélène, Jerusalem, Guy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881925/ https://www.ncbi.nlm.nih.gov/pubmed/27284266 http://dx.doi.org/10.2147/BCTT.S69488 |
Ejemplares similares
-
Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer
por: Lousberg, Laurence, et al.
Publicado: (2017) -
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
por: Jerusalem, Guy, et al.
Publicado: (2014) -
Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers
por: Boukerroucha, Meriem, et al.
Publicado: (2015) -
Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment
por: Onesti, Concetta Elisa, et al.
Publicado: (2018) -
Circulating microRNA-based screening tool for breast cancer
por: Frères, Pierre, et al.
Publicado: (2015)